| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitiligo | 69 | 2026 | 118 | 26.040 |
Why?
|
| Skin | 24 | 2025 | 375 | 6.760 |
Why?
|
| Melanocytes | 19 | 2025 | 75 | 5.740 |
Why?
|
| Hypopigmentation | 11 | 2023 | 16 | 5.340 |
Why?
|
| Autoimmunity | 13 | 2025 | 237 | 3.360 |
Why?
|
| Skin Pigmentation | 8 | 2025 | 31 | 3.340 |
Why?
|
| CD8-Positive T-Lymphocytes | 14 | 2025 | 677 | 3.100 |
Why?
|
| Autoimmune Diseases | 7 | 2025 | 229 | 2.450 |
Why?
|
| Alopecia Areata | 6 | 2018 | 10 | 2.410 |
Why?
|
| Janus Kinase Inhibitors | 5 | 2025 | 18 | 2.330 |
Why?
|
| Immunotherapy | 4 | 2020 | 256 | 2.010 |
Why?
|
| Chemokines | 4 | 2021 | 93 | 1.720 |
Why?
|
| Interferon-gamma | 11 | 2024 | 566 | 1.700 |
Why?
|
| T-Lymphocytes | 6 | 2025 | 1009 | 1.660 |
Why?
|
| Disease Models, Animal | 13 | 2025 | 2196 | 1.660 |
Why?
|
| Chemokine CXCL10 | 11 | 2023 | 56 | 1.590 |
Why?
|
| Dermatology | 4 | 2023 | 75 | 1.540 |
Why?
|
| Pyrazoles | 6 | 2022 | 79 | 1.520 |
Why?
|
| Immunologic Memory | 6 | 2021 | 288 | 1.480 |
Why?
|
| Humans | 90 | 2026 | 63538 | 1.450 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2022 | 212 | 1.400 |
Why?
|
| Blister | 2 | 2024 | 16 | 1.390 |
Why?
|
| Melanoma, Experimental | 2 | 2021 | 44 | 1.360 |
Why?
|
| Receptors, CXCR3 | 5 | 2023 | 35 | 1.350 |
Why?
|
| Skin Diseases | 4 | 2022 | 83 | 1.310 |
Why?
|
| Animals | 39 | 2025 | 20715 | 1.270 |
Why?
|
| Keratinocytes | 4 | 2023 | 63 | 1.150 |
Why?
|
| Gene Expression Profiling | 4 | 2024 | 769 | 1.110 |
Why?
|
| Mice | 26 | 2025 | 10863 | 1.050 |
Why?
|
| Chemokine CXCL9 | 6 | 2023 | 23 | 1.010 |
Why?
|
| Simvastatin | 2 | 2017 | 26 | 0.960 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2017 | 181 | 0.930 |
Why?
|
| Ultraviolet Therapy | 6 | 2025 | 15 | 0.910 |
Why?
|
| Dermatitis, Irritant | 1 | 2024 | 4 | 0.890 |
Why?
|
| Signal Transduction | 8 | 2020 | 3033 | 0.890 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2024 | 13 | 0.880 |
Why?
|
| Lupus Erythematosus, Cutaneous | 2 | 2021 | 13 | 0.840 |
Why?
|
| Pyrimidines | 7 | 2022 | 136 | 0.810 |
Why?
|
| Immunity, Innate | 8 | 2021 | 797 | 0.730 |
Why?
|
| RNA, Small Cytoplasmic | 1 | 2021 | 6 | 0.720 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2021 | 8 | 0.700 |
Why?
|
| Receptors, CCR5 | 1 | 2021 | 58 | 0.690 |
Why?
|
| Cancer Vaccines | 1 | 2021 | 49 | 0.690 |
Why?
|
| Anti-Infective Agents | 1 | 2023 | 150 | 0.690 |
Why?
|
| Lupus Nephritis | 1 | 2021 | 37 | 0.680 |
Why?
|
| Nitriles | 5 | 2022 | 70 | 0.670 |
Why?
|
| Biological Products | 1 | 2022 | 96 | 0.670 |
Why?
|
| Cross-Priming | 1 | 2020 | 16 | 0.670 |
Why?
|
| Hair Dyes | 2 | 2017 | 5 | 0.650 |
Why?
|
| Epidermis | 2 | 2018 | 36 | 0.650 |
Why?
|
| Immunity, Cellular | 4 | 2019 | 178 | 0.640 |
Why?
|
| Interferon Type I | 2 | 2020 | 187 | 0.620 |
Why?
|
| DNA-Binding Proteins | 3 | 2021 | 1185 | 0.600 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2022 | 188 | 0.600 |
Why?
|
| Efficiency | 1 | 2019 | 41 | 0.590 |
Why?
|
| Mice, Inbred C57BL | 10 | 2021 | 3401 | 0.590 |
Why?
|
| Immunosuppressive Agents | 3 | 2022 | 380 | 0.580 |
Why?
|
| Adult | 19 | 2026 | 16905 | 0.570 |
Why?
|
| Antibodies, Blocking | 1 | 2018 | 39 | 0.570 |
Why?
|
| Interleukin-15 | 1 | 2018 | 25 | 0.570 |
Why?
|
| Male | 23 | 2026 | 29940 | 0.550 |
Why?
|
| Melanoma | 1 | 2021 | 331 | 0.550 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2017 | 215 | 0.540 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 247 | 0.540 |
Why?
|
| Skin Lightening Preparations | 1 | 2017 | 3 | 0.530 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 73 | 0.520 |
Why?
|
| Mice, Transgenic | 6 | 2025 | 1284 | 0.510 |
Why?
|
| Stress, Physiological | 2 | 2016 | 193 | 0.510 |
Why?
|
| Bullying | 1 | 2016 | 16 | 0.490 |
Why?
|
| Phenols | 1 | 2017 | 78 | 0.490 |
Why?
|
| Antibodies | 1 | 2017 | 182 | 0.490 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 436 | 0.480 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 435 | 0.470 |
Why?
|
| Young Adult | 8 | 2026 | 4719 | 0.470 |
Why?
|
| Melanins | 1 | 2015 | 24 | 0.460 |
Why?
|
| Organ Specificity | 1 | 2016 | 195 | 0.460 |
Why?
|
| Female | 21 | 2026 | 32946 | 0.460 |
Why?
|
| Hair | 1 | 2015 | 83 | 0.450 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 81 | 0.450 |
Why?
|
| Middle Aged | 13 | 2026 | 17659 | 0.450 |
Why?
|
| Adolescent | 8 | 2026 | 6262 | 0.450 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2021 | 642 | 0.440 |
Why?
|
| Severity of Illness Index | 8 | 2025 | 1553 | 0.430 |
Why?
|
| Genetic Vectors | 1 | 2020 | 881 | 0.430 |
Why?
|
| Biomarkers | 4 | 2024 | 1405 | 0.430 |
Why?
|
| Psoriasis | 2 | 2016 | 57 | 0.430 |
Why?
|
| Quality of Life | 6 | 2025 | 1241 | 0.420 |
Why?
|
| Treatment Outcome | 11 | 2023 | 5627 | 0.410 |
Why?
|
| Biopsy | 3 | 2024 | 447 | 0.400 |
Why?
|
| Dermatologic Agents | 2 | 2024 | 22 | 0.380 |
Why?
|
| Double-Blind Method | 5 | 2022 | 738 | 0.380 |
Why?
|
| Single-Cell Analysis | 2 | 2024 | 114 | 0.370 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2021 | 5 | 0.360 |
Why?
|
| Dermatitis, Atopic | 2 | 2022 | 29 | 0.360 |
Why?
|
| Scleroderma, Localized | 2 | 2023 | 11 | 0.360 |
Why?
|
| Ureteral Obstruction | 1 | 2021 | 26 | 0.350 |
Why?
|
| Suction | 2 | 2024 | 35 | 0.350 |
Why?
|
| Molecular Targeted Therapy | 2 | 2024 | 129 | 0.350 |
Why?
|
| Genome-Wide Association Study | 3 | 2021 | 359 | 0.350 |
Why?
|
| Adenosine | 1 | 2021 | 78 | 0.350 |
Why?
|
| Adaptive Immunity | 3 | 2017 | 101 | 0.340 |
Why?
|
| Specimen Handling | 2 | 2024 | 61 | 0.330 |
Why?
|
| Dermatitis, Contact | 1 | 2010 | 12 | 0.320 |
Why?
|
| gp100 Melanoma Antigen | 3 | 2025 | 6 | 0.320 |
Why?
|
| Phototherapy | 5 | 2023 | 35 | 0.320 |
Why?
|
| Apoptosis | 1 | 2015 | 1080 | 0.320 |
Why?
|
| Dermatitis | 2 | 2023 | 28 | 0.310 |
Why?
|
| B-Lymphocytes | 2 | 2018 | 572 | 0.310 |
Why?
|
| Receptors, CCR6 | 2 | 2022 | 9 | 0.310 |
Why?
|
| Thrombosis | 1 | 2021 | 198 | 0.300 |
Why?
|
| Clonal Anergy | 2 | 2009 | 23 | 0.300 |
Why?
|
| Exophiala | 1 | 2008 | 1 | 0.300 |
Why?
|
| Leg Dermatoses | 1 | 2008 | 3 | 0.300 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2021 | 188 | 0.300 |
Why?
|
| Dermatomycoses | 1 | 2008 | 13 | 0.300 |
Why?
|
| Kidney Transplantation | 1 | 2021 | 323 | 0.290 |
Why?
|
| Case-Control Studies | 3 | 2026 | 1120 | 0.280 |
Why?
|
| Oxidative Stress | 2 | 2021 | 297 | 0.260 |
Why?
|
| Phenotype | 3 | 2021 | 1208 | 0.250 |
Why?
|
| Melanosis | 1 | 2026 | 10 | 0.240 |
Why?
|
| Janus Kinase 1 | 2 | 2023 | 11 | 0.240 |
Why?
|
| Janus Kinases | 2 | 2022 | 16 | 0.240 |
Why?
|
| Transcriptome | 2 | 2024 | 386 | 0.240 |
Why?
|
| Cytokines | 3 | 2023 | 934 | 0.240 |
Why?
|
| Inflammation | 4 | 2023 | 1146 | 0.240 |
Why?
|
| STAT1 Transcription Factor | 2 | 2016 | 34 | 0.240 |
Why?
|
| Lymphocyte Activation | 3 | 2018 | 758 | 0.230 |
Why?
|
| Administration, Oral | 2 | 2017 | 369 | 0.230 |
Why?
|
| Consensus | 3 | 2021 | 201 | 0.220 |
Why?
|
| Population Surveillance | 1 | 2026 | 207 | 0.220 |
Why?
|
| Interleukin-17 | 2 | 2017 | 94 | 0.220 |
Why?
|
| Skin Cream | 2 | 2022 | 3 | 0.220 |
Why?
|
| Interleukin-4 | 1 | 2024 | 141 | 0.220 |
Why?
|
| RNA, Small Interfering | 4 | 2023 | 922 | 0.210 |
Why?
|
| Skin Physiological Phenomena | 2 | 2014 | 16 | 0.210 |
Why?
|
| Bleomycin | 2 | 2023 | 34 | 0.210 |
Why?
|
| Photochemotherapy | 1 | 2023 | 24 | 0.200 |
Why?
|
| Uncertainty | 1 | 2023 | 37 | 0.200 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 174 | 0.200 |
Why?
|
| Fibrosis | 2 | 2023 | 160 | 0.200 |
Why?
|
| RNA, Double-Stranded | 1 | 2023 | 112 | 0.200 |
Why?
|
| Ligands | 2 | 2023 | 416 | 0.200 |
Why?
|
| Skin Transplantation | 1 | 2023 | 154 | 0.190 |
Why?
|
| Proteomics | 1 | 2024 | 283 | 0.190 |
Why?
|
| Dendritic Cells | 2 | 2025 | 525 | 0.190 |
Why?
|
| Cell Differentiation | 3 | 2016 | 1355 | 0.180 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2020 | 59 | 0.180 |
Why?
|
| Tissue Distribution | 1 | 2022 | 292 | 0.180 |
Why?
|
| Diagnosis, Differential | 1 | 2024 | 979 | 0.180 |
Why?
|
| Autoantigens | 3 | 2021 | 137 | 0.180 |
Why?
|
| Gene Ontology | 1 | 2021 | 38 | 0.180 |
Why?
|
| CD28 Antigens | 2 | 2015 | 60 | 0.170 |
Why?
|
| Epidemiologic Studies | 1 | 2021 | 34 | 0.170 |
Why?
|
| Ointments | 1 | 2020 | 7 | 0.170 |
Why?
|
| Piperidines | 2 | 2020 | 63 | 0.170 |
Why?
|
| Mice, Mutant Strains | 1 | 2021 | 302 | 0.170 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2023 | 258 | 0.170 |
Why?
|
| Child | 4 | 2026 | 4540 | 0.170 |
Why?
|
| Hyaluronan Receptors | 1 | 2020 | 35 | 0.170 |
Why?
|
| Aged | 6 | 2025 | 14451 | 0.170 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2020 | 53 | 0.170 |
Why?
|
| Vaccinia virus | 1 | 2020 | 73 | 0.160 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 57 | 0.160 |
Why?
|
| Republic of Korea | 1 | 2021 | 176 | 0.160 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 158 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2021 | 105 | 0.160 |
Why?
|
| Genetic Testing | 1 | 2021 | 134 | 0.160 |
Why?
|
| Cell Movement | 2 | 2019 | 457 | 0.160 |
Why?
|
| Photography | 1 | 2019 | 40 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 165 | 0.150 |
Why?
|
| Dermatologists | 1 | 2019 | 13 | 0.150 |
Why?
|
| Transcription Factors | 2 | 2004 | 1515 | 0.150 |
Why?
|
| Cell Death | 2 | 2018 | 285 | 0.150 |
Why?
|
| Inflammasomes | 1 | 2023 | 334 | 0.150 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 50 | 0.150 |
Why?
|
| Stem Cell Factor | 1 | 2018 | 26 | 0.150 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2018 | 2 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 527 | 0.140 |
Why?
|
| Heat-Shock Proteins | 1 | 2018 | 64 | 0.140 |
Why?
|
| Fas Ligand Protein | 1 | 2018 | 42 | 0.140 |
Why?
|
| Pigmentation | 2 | 2015 | 24 | 0.140 |
Why?
|
| Reactive Oxygen Species | 2 | 2016 | 225 | 0.140 |
Why?
|
| Early Growth Response Protein 2 | 2 | 2010 | 8 | 0.140 |
Why?
|
| Depression | 1 | 2025 | 908 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 721 | 0.140 |
Why?
|
| DNA | 2 | 2023 | 838 | 0.140 |
Why?
|
| Disease Management | 1 | 2020 | 232 | 0.140 |
Why?
|
| Foundations | 1 | 2018 | 9 | 0.140 |
Why?
|
| Cell Proliferation | 3 | 2014 | 988 | 0.140 |
Why?
|
| Pigmentation Disorders | 1 | 2018 | 9 | 0.140 |
Why?
|
| Global Health | 1 | 2019 | 183 | 0.140 |
Why?
|
| Follow-Up Studies | 1 | 2023 | 2463 | 0.140 |
Why?
|
| Swine | 1 | 2018 | 387 | 0.140 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2018 | 103 | 0.130 |
Why?
|
| Phenylenediamines | 1 | 2017 | 5 | 0.130 |
Why?
|
| Hydroquinones | 1 | 2017 | 8 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2023 | 5467 | 0.130 |
Why?
|
| Chemokine CXCL11 | 1 | 2017 | 4 | 0.130 |
Why?
|
| Catechols | 1 | 2017 | 7 | 0.130 |
Why?
|
| Pyrroles | 1 | 2017 | 52 | 0.130 |
Why?
|
| Self Tolerance | 1 | 2017 | 20 | 0.130 |
Why?
|
| Body Surface Area | 1 | 2017 | 11 | 0.130 |
Why?
|
| Antigens, CD | 1 | 2018 | 347 | 0.130 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2018 | 211 | 0.130 |
Why?
|
| Flow Cytometry | 1 | 2018 | 664 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2021 | 3293 | 0.130 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 36 | 0.130 |
Why?
|
| Regeneration | 1 | 2017 | 99 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2017 | 202 | 0.120 |
Why?
|
| Combined Modality Therapy | 3 | 2023 | 374 | 0.120 |
Why?
|
| Gene-Environment Interaction | 1 | 2016 | 49 | 0.120 |
Why?
|
| ROC Curve | 1 | 2017 | 281 | 0.120 |
Why?
|
| Immune Complex Diseases | 1 | 2016 | 2 | 0.120 |
Why?
|
| Chemokine CXCL2 | 1 | 2016 | 14 | 0.120 |
Why?
|
| Antigen-Antibody Complex | 1 | 2016 | 52 | 0.120 |
Why?
|
| Bone Marrow Cells | 1 | 2016 | 237 | 0.120 |
Why?
|
| Risk | 1 | 2016 | 378 | 0.120 |
Why?
|
| Antioxidants | 1 | 2017 | 252 | 0.110 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 669 | 0.110 |
Why?
|
| Insurance Coverage | 1 | 2015 | 99 | 0.110 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 135 | 0.110 |
Why?
|
| Monocytes | 1 | 2016 | 353 | 0.110 |
Why?
|
| Subcutaneous Fat | 1 | 2014 | 47 | 0.110 |
Why?
|
| Insurance, Health | 1 | 2015 | 151 | 0.110 |
Why?
|
| Immunity | 1 | 2014 | 107 | 0.100 |
Why?
|
| Scalp | 1 | 2013 | 28 | 0.100 |
Why?
|
| Child, Preschool | 1 | 2019 | 1998 | 0.100 |
Why?
|
| Wound Healing | 1 | 2014 | 186 | 0.100 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 37 | 0.100 |
Why?
|
| High Mobility Group Proteins | 1 | 2013 | 24 | 0.100 |
Why?
|
| Neutrophils | 1 | 2016 | 376 | 0.100 |
Why?
|
| Up-Regulation | 2 | 2023 | 373 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2019 | 2026 | 0.090 |
Why?
|
| Intestines | 1 | 2013 | 165 | 0.090 |
Why?
|
| Renal Circulation | 1 | 2021 | 14 | 0.090 |
Why?
|
| Adoptive Transfer | 1 | 2012 | 148 | 0.090 |
Why?
|
| Methylation | 1 | 2021 | 129 | 0.090 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2010 | 53 | 0.080 |
Why?
|
| Toxoplasmosis | 1 | 2010 | 20 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2026 | 6619 | 0.080 |
Why?
|
| Chronic Disease | 2 | 2023 | 751 | 0.080 |
Why?
|
| DNA, Ribosomal Spacer | 1 | 2008 | 2 | 0.080 |
Why?
|
| Itraconazole | 1 | 2008 | 13 | 0.070 |
Why?
|
| DNA, Fungal | 1 | 2008 | 58 | 0.070 |
Why?
|
| Culture Media | 1 | 2008 | 79 | 0.070 |
Why?
|
| Interleukin-2 | 2 | 2009 | 167 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 149 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 385 | 0.070 |
Why?
|
| Antifungal Agents | 1 | 2008 | 128 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2008 | 205 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 2592 | 0.070 |
Why?
|
| Molecular Sequence Data | 2 | 2008 | 1993 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 417 | 0.070 |
Why?
|
| Zinc Fingers | 2 | 2004 | 103 | 0.060 |
Why?
|
| Mice, Hairless | 1 | 2025 | 19 | 0.060 |
Why?
|
| Patient Health Questionnaire | 1 | 2025 | 7 | 0.060 |
Why?
|
| Mice, Knockout | 3 | 2018 | 2113 | 0.060 |
Why?
|
| Antigens, Ly | 2 | 2016 | 42 | 0.060 |
Why?
|
| CD3 Complex | 1 | 2004 | 65 | 0.060 |
Why?
|
| Clone Cells | 1 | 2004 | 115 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 1664 | 0.060 |
Why?
|
| Cell Line | 2 | 2009 | 2041 | 0.050 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2004 | 71 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2025 | 182 | 0.050 |
Why?
|
| Steroids | 1 | 2023 | 55 | 0.050 |
Why?
|
| NLR Proteins | 1 | 2023 | 11 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2004 | 287 | 0.050 |
Why?
|
| Ownership | 1 | 2022 | 19 | 0.050 |
Why?
|
| Administration, Topical | 1 | 2022 | 51 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2022 | 64 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 44 | 0.050 |
Why?
|
| Acne Vulgaris | 1 | 2022 | 24 | 0.050 |
Why?
|
| Pruritus | 1 | 2022 | 30 | 0.050 |
Why?
|
| Caspase 1 | 1 | 2023 | 111 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 883 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2023 | 156 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2004 | 937 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2004 | 401 | 0.050 |
Why?
|
| Incidence | 1 | 2026 | 1372 | 0.050 |
Why?
|
| Emollients | 1 | 2021 | 4 | 0.040 |
Why?
|
| Age Factors | 1 | 2025 | 1561 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 237 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2023 | 397 | 0.040 |
Why?
|
| North Carolina | 1 | 2020 | 71 | 0.040 |
Why?
|
| Mental Health | 1 | 2023 | 371 | 0.040 |
Why?
|
| Patient Selection | 1 | 2022 | 487 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2016 | 2166 | 0.040 |
Why?
|
| Lighting | 1 | 2019 | 13 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2026 | 2569 | 0.040 |
Why?
|
| Reference Standards | 1 | 2019 | 73 | 0.040 |
Why?
|
| Health Personnel | 1 | 2023 | 377 | 0.040 |
Why?
|
| International Cooperation | 1 | 2019 | 90 | 0.040 |
Why?
|
| Internationality | 1 | 2019 | 44 | 0.040 |
Why?
|
| RNA | 1 | 2023 | 426 | 0.040 |
Why?
|
| Ultraviolet Rays | 1 | 2019 | 137 | 0.040 |
Why?
|
| Immune System | 1 | 2020 | 130 | 0.040 |
Why?
|
| Observer Variation | 1 | 2019 | 215 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 776 | 0.040 |
Why?
|
| RNA Interference | 1 | 2022 | 618 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2000 | 345 | 0.040 |
Why?
|
| Ovalbumin | 1 | 2018 | 116 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2000 | 486 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 1617 | 0.030 |
Why?
|
| Janus Kinase 3 | 1 | 2017 | 4 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2018 | 173 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2018 | 183 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 265 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2017 | 85 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2016 | 1535 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 89 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1114 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2000 | 628 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 458 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2000 | 878 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 719 | 0.030 |
Why?
|
| Endotoxins | 1 | 2016 | 81 | 0.030 |
Why?
|
| Mast Cells | 1 | 2016 | 39 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2000 | 778 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 2703 | 0.030 |
Why?
|
| Neutrophil Infiltration | 1 | 2016 | 60 | 0.030 |
Why?
|
| Regenerative Medicine | 1 | 2015 | 20 | 0.030 |
Why?
|
| Smoking | 1 | 2000 | 863 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2015 | 119 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 455 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 177 | 0.030 |
Why?
|
| Nurses | 1 | 2015 | 109 | 0.030 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 1 | 1 | 2013 | 3 | 0.030 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2013 | 10 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2013 | 12 | 0.030 |
Why?
|
| SOXC Transcription Factors | 1 | 2013 | 9 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2013 | 14 | 0.030 |
Why?
|
| Interleukins | 1 | 2013 | 80 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2016 | 384 | 0.020 |
Why?
|
| Rheology | 1 | 2013 | 74 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2013 | 71 | 0.020 |
Why?
|
| Base Sequence | 2 | 2009 | 1331 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 190 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1004 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2013 | 271 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 158 | 0.020 |
Why?
|
| Lung | 1 | 2016 | 957 | 0.020 |
Why?
|
| Toxoplasma | 1 | 2010 | 33 | 0.020 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2010 | 89 | 0.020 |
Why?
|
| Macrophages | 1 | 2016 | 1041 | 0.020 |
Why?
|
| Columbidae | 1 | 2009 | 12 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2009 | 28 | 0.020 |
Why?
|
| Transplantation Tolerance | 1 | 2009 | 67 | 0.020 |
Why?
|
| DNA Primers | 1 | 2009 | 292 | 0.020 |
Why?
|
| Antigens | 1 | 2009 | 147 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2009 | 197 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 695 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 5281 | 0.010 |
Why?
|
| Taxes | 1 | 2000 | 6 | 0.010 |
Why?
|
| Snail Family Transcription Factors | 1 | 2000 | 28 | 0.010 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2000 | 15 | 0.010 |
Why?
|
| Government Programs | 1 | 2000 | 20 | 0.010 |
Why?
|
| Hydroxamic Acids | 1 | 2000 | 28 | 0.010 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2000 | 36 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2000 | 116 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2000 | 234 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2000 | 173 | 0.010 |
Why?
|
| Histone Deacetylases | 1 | 2000 | 66 | 0.010 |
Why?
|
| Risk-Taking | 1 | 2000 | 162 | 0.010 |
Why?
|
| Health Surveys | 1 | 2000 | 313 | 0.010 |
Why?
|
| RNA Splicing | 1 | 2000 | 162 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2000 | 198 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 281 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 373 | 0.010 |
Why?
|
| Binding Sites | 1 | 2000 | 906 | 0.010 |
Why?
|
| Prevalence | 1 | 2000 | 1383 | 0.010 |
Why?
|
| Health Promotion | 1 | 2000 | 500 | 0.010 |
Why?
|
| Prognosis | 1 | 2000 | 1743 | 0.010 |
Why?
|
| Chromatin | 1 | 2000 | 607 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2000 | 548 | 0.010 |
Why?
|
| Massachusetts | 1 | 2000 | 2072 | 0.010 |
Why?
|